Genmab — December 2024

[E_L]

Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-monotherapy

[E_L]

Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL - Epcoritamab - https://ashpublications.org/ashclinicalnews/news/8275/Bispecific-Antibody-Elicits-High-Responses-Among?searchresult=1&utm_source=twitter&utm_medium=organic_social&utm_term=ashclinicalnews&utm_content=c49e3a3b-b64c-4357-a1a7-f2c933057b8c&utm_campaign=

[E_L]

Exploring New Frontiers in Chronic Lymphocytic Leukemia (CLL) Treatment: A Q&A With City of Hope’s Dr. Danilov https://www.linkedin.com/pulse/exploring-new-frontiers-chronic-lymphocytic-leukemia-cll-n9u1c/?trackingId=/rRSFPDq0eXIPCTAGmg6pg%3D%3D

[E_L]

slides - #ASH24 | Alexey Danilov: epcoritamab monotherapy in patients with R/R #chroniclymphocyticleukemia: results from #CLL expansion and optimization cohorts of Epcore CLL-1 https://x.com/EmatoInfo/status/1865795985567354959

[E_L]

‘Double-Barreled’ Drug Shows Early Promise for Blood Cancer https://www.cityofhope.org/double-barreled-drug-shows-early-promise-for-blood-cancer

[E_L]

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-shows-51-percent-reduction-in-risk-of-progression-to-active-multiple-myeloma-for-patients-with-high-risk-smoldering-multiple-myeloma

[E_L]

TECVAYLI (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma https://innovativemedicine.jnj.com/our-innovation/focus-areas/oncology/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma

[Helge_LarsenPI-redaktør]

E L..Thank you from the bottom of my heart for your daily tireless distribution of big and small news from Genmab and the pipeline.

[Solsen]

TECVAYLI is also impressing with 100% MRD in combo faspro etc. Looks like cure, but long term followup will show. Hard to se superdara can do better, but time will show.

[Bulder]

A few years ago we all dreamt of the tec-dara combo. Now we must face that it Can be hard to beat for erzo. What we Can hope for is that erzo is still much better than data, and thus the tec-erzo combo Will be the combo to end all combos.

[Bulder]

data=dara

[E_L]

thanks Helge

[E_L]

true on Tec,
but that development can't be stopped- if it isn't Tec then another BCMA engager; at least genmab gets a royalty now

[E_L]

and if SuperDara works maybe they can also make a SuperTec

[Solsen]

Some slides on tec https://x.com/bertrandbio/status/1865821047708156414?s=61&t=JauvgjicW74kU8sNN3xEFA

[Solsen]

https://x.com/bertrandbio/status/1865821050090696978?s=61&t=JauvgjicW74kU8sNN3xEFA https://x.com/bertrandbio/status/1865823457973608495?s=61&t=JauvgjicW74kU8sNN3xEFA https://x.com/bertrandbio/status/1865823791076487442?s=61&t=JauvgjicW74kU8sNN3xEFA

[ProinvestorNEWS]

Servicemeddelelse: Efter serverskiftet i weekenden kører vores newsfeed desværre ikke pt. Vi arbejder på at få løst problemet.

[Solsen]

Tror godt at JNJ udnytter optionen, hvis erzo differentierer sig fra faspro. Der er usikkerhed til prisen de kan forlange for faspro efter patentudløb på dara. Men kommer det prispres ikke fra US m.v. så vil der ikke blive solgt meget erzo før faspros patent udløber.

[w]

hvad er royalty satsen på Tec?

[Sukkeralf]

Formentlig 6-8%